The Gene Expression of Proteins Involved in Intercellular Signaling and Neurodegeneration in the Substantia Nigra in a Mouse Subchronic Model of Parkinson's Disease.
PCR
Parkinson’s disease
dopaminergic neurons
gene expression
mice
modeling of Parkinson’s disease
neurodegeneration
substantia nigra
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Feb 2023
03 Feb 2023
Historique:
received:
05
12
2022
revised:
27
01
2023
accepted:
02
02
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Given the limited access to clinical material for studying the pathogenesis of Parkinson's disease (PD), these studies should be carried out on experimental models. We have recently developed a subchronic model of the progressive development of PD with a gradual transition from the preclinical (asymptomatic) stage to the clinical (symptomatic) one. The aim of this study was to evaluate changes in the expression of a wide range of genes in the substantia nigra (SN), the central link in the regulation of motor function, in mice in our subchronic model of PD. We have found changes in the expression of a number of genes encoding enzymes involved in the synthesis and degradation of dopamine as well as proteins involved in the vesicular cycle, axonal transport, protein degradation in the proteasome system, neuroinflammation, and cell death in the SN of our mouse model of the clinical stage of PD. Similar changes in gene expression were previously demonstrated in patients (postmortem), indicating good reproducibility of PD in our model. Further analysis of the gene expression in the SN of mice has shown that the expression of some genes also changes in the model of the preclinical stage, when dopaminergic neurons have not yet died. Thus, this study opens up broad prospects for further evaluation of the molecular mechanisms of PD pathogenesis and the development of a test system for drug screening.
Identifiants
pubmed: 36769355
pii: ijms24033027
doi: 10.3390/ijms24033027
pmc: PMC9917821
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Ministry of Science and Higher Education of the Russian Federation
ID : grant agreement № 075-15-2020-795, state contract № 13.1902.21.0027 of 29.09.2020, unique project ID: RF-190220X0027
Références
Brain Sci. 2022 Jun 14;12(6):
pubmed: 35741664
Nat Commun. 2018 Jan 8;9(1):81
pubmed: 29311685
Neuroscience. 2006 Jun 19;140(1):67-76
pubmed: 16533572
Front Cell Neurosci. 2015 Sep 09;9:343
pubmed: 26441521
Acta Neuropathol. 1988;75(4):345-53
pubmed: 3364159
Eur J Neurosci. 2002 Dec;16(11):2136-48
pubmed: 12473081
Arch Neurol. 2005 Jun;62(6):917-21
pubmed: 15956162
J Neurol. 2008 Sep;255 Suppl 5:18-32
pubmed: 18787879
PLoS One. 2010 Jan 25;5(1):e8856
pubmed: 20111594
Int J Mol Sci. 2022 Dec 30;24(1):
pubmed: 36614126
J Neurosci. 2003 Apr 15;23(8):3316-24
pubmed: 12716939
PLoS One. 2009;4(3):e4955
pubmed: 19305504
Eur J Neurol. 2012 Jun;19(6):870-5
pubmed: 22309633
Mov Disord. 1998 Nov;13(6):877-84
pubmed: 9827610
J Neural Transm Park Dis Dement Sect. 1994;8(1-2):149-58
pubmed: 7893377
Neurobiol Dis. 2015 Feb;74:1-13
pubmed: 25447234
Acta Neuropathol. 1997 Feb;93(2):105-8
pubmed: 9039456
Mov Disord. 2005 Oct;20(10):1299-309
pubmed: 15966006
Genome Res. 2005 Oct;15(10):1388-92
pubmed: 16204192
J Neurochem. 2009 Nov;111(4):1042-50
pubmed: 19765187
Front Cell Neurosci. 2021 Mar 02;15:626128
pubmed: 33737866
Neuroscience. 2014 Dec 12;282:13-22
pubmed: 24463000
J Neurosci. 2015 Jan 7;35(1):96-111
pubmed: 25568106
Neuroscience. 2011 May 5;181:175-88
pubmed: 21382448
Neurogenetics. 2006 Mar;7(1):1-11
pubmed: 16344956
Brain Res. 2010 Jul 30;1346:26-42
pubmed: 20513370
Neurochem Res. 1990 Apr;15(4):425-9
pubmed: 1975089
Neurobiol Dis. 2006 Feb;21(2):305-13
pubmed: 16143538
Science. 2000 Nov 3;290(5493):985-9
pubmed: 11062131
Brain Pathol. 2009 Jan;19(1):91-107
pubmed: 18462474
Neurobiol Dis. 2007 Jun;26(3):606-14
pubmed: 17412603
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2875-80
pubmed: 10688892
Brain. 2009 Jul;132(Pt 7):1795-809
pubmed: 19052140
J Parkinsons Dis. 2016;6(1):1-15
pubmed: 27003783
CNS Neurosci Ther. 2020 Oct;26(10):997-1009
pubmed: 32597012
Trends Cell Biol. 2000 Dec;10(12):524-30
pubmed: 11121744
Cell Mol Neurobiol. 2022 Nov;42(8):2805-2818
pubmed: 34528139
Front Aging Neurosci. 2016 Dec 15;8:303
pubmed: 28018215
Brain Res Mol Brain Res. 1996 Feb;36(1):157-62
pubmed: 9011752
Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):5-16
pubmed: 15965975
Neurology. 2006 May 23;66(10 Suppl 4):S69-79
pubmed: 16717254
Histol Histopathol. 1997 Jan;12(1):25-31
pubmed: 9046040
Parkinsonism Relat Disord. 1999 Dec;5(4):187-92
pubmed: 18591139
J Neurol Sci. 1996 May;137(2):120-3
pubmed: 8782165
J Neurol Sci. 2014 May 15;340(1-2):198-207
pubmed: 24768159
Neurogenetics. 2007 Apr;8(2):83-94
pubmed: 17211632
Mov Disord. 2001 Mar;16(2):185-9
pubmed: 11295768
Rev Neurol (Paris). 2016 Jan;172(1):14-26
pubmed: 26718594
Mov Disord. 1998 Mar;13(2):221-7
pubmed: 9539333
Science. 2002 Feb 1;295(5556):865-8
pubmed: 11823645
Brain. 2012 Jul;135(Pt 7):2058-73
pubmed: 22719003
Front Mol Neurosci. 2021 Nov 11;14:763777
pubmed: 34867188
Acta Neuropathol. 2007 Mar;113(3):253-63
pubmed: 17203291
J Neural Transm (Vienna). 2004 Dec;111(12):1543-73
pubmed: 15455214
J Neural Transm (Vienna). 2000;107(1):1-29
pubmed: 10809400
Acta Neuropathol. 2011 Jul;122(1):75-86
pubmed: 21541762
Mov Disord. 2019 May;34(5):665-675
pubmed: 30919499
J Neural Transm. 1988;72(1):77-82
pubmed: 2897999